{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:49:33Z","timestamp":1792802973039,"version":"4.5.0"},"reference-count":68,"publisher":"Touch Medical Media, Ltd.","issue":"1","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This article is published under the Creative Commons Attribution Non-commercial License.","id":[{"id":"https:\/\/ror.org\/02ed4cj64","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"abstract":"<p>Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of fatty liver disease, including non-alcoholic fatty liver (NAFL) and its more progressive form, non-alcoholic steatohepatitis (NASH). The prevalence of NAFLD\/NASH along with type 2 diabetes and obesity is rising worldwide. In those who develop NASH, unlike those with bland steatosis (NAFL), lipotoxic lipids drive hepatocyte injury, inflammation and stellate cell activation leading to progressive accumulation of collagen or fibrosis, ultimately leading to cirrhosis and increased risk of hepatocellular carcinoma. Hypothyroidism is associated with NAFLD\/NASH; specifically, intrahepatic hypothyroidism drives lipotoxicty in preclinical models. Agonists of thyroid hormone receptor (THR)-\u03b2, which is primarily found in the liver, can promote lipophagy, mitochondrial biogenesis and mitophagy, stimulating increased hepatic fatty acid \u03b2-oxidation, and thereby decreasing the burden of lipotoxic lipids, while promoting low-density lipoprotein (LDL) uptake and favourable effects on lipid profiles. A number of THR-\u03b2 agonists are currently being investigated for NASH. This review focuses on resmetirom, an orally administered, once-daily, small-molecule, liver-directed, \u00df-selective THR agonist, as it is furthest along in development. Data from completed clincal studies outlined in this review demonstrate that resmetirom is effective in reducing hepatic fat content as measured by magnetic resonance imaging-derived proton density fat fraction, reduces liver enzymes, improves non-invasive markers of liver fibrogenesis and decreases liver stiffness, while eliciting a favourable cardiovascular profile with a reduction in serum lipids, including LDL cholesterol. Topline phase III biopsy data showed resolution of NASH and\/or fibrosis improvement after 52 weeks of treatment, with more detailed peer-reviewed findings anticipated in order to certify these findings. Longer term clinical outcomes from both MAESTRO-NASH and MAESTRO-NASH OUTCOMES will be a pivotal juncture in the drug\u2019s road towards being approved as a NASH therapeutic.<\/p>","DOI":"10.17925\/ee.2023.19.1.60","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T12:40:19Z","timestamp":1685709619000},"page":"60","source":"Crossref","is-referenced-by-count":129,"title":["Resmetirom: An Orally Administered, Small-molecule, Liver-directed, \u03b2-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis"],"prefix":"10.17925","volume":"19","author":[{"given":"Gres","family":"Karim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Medicine, Mount Sinai Israel, New York, NY, USA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena B","family":"Bansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7274","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases.\n                      Hepatology\n                      . 2018;67:328\u201357. DOI: 10.1002\/hep.29367","DOI":"10.1002\/hep.29367"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis.\n                      N Engl J Med\n                      . 2017;377:2063\u201372. DOI: 10.1056\/NEJMra1503519","DOI":"10.1056\/NEJMra1503519"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Ekstedt M, Franz\u00e9n LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes.\n                      Hepatology\n                      . 2006;44:865\u201373. DOI: 10.1002\/hep.21327","DOI":"10.1002\/hep.21327"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality.\n                      Hepatology\n                      . 2011;53:1874\u201382. DOI: 10.1002\/hep.24268","DOI":"10.1002\/hep.24268"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes.\n                      Hepatology\n                      . 2016;64:73\u201384. DOI: 10.1002\/hep.28431","DOI":"10.1002\/hep.28431"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.\n                      J Hepatol Oct\n                      . 2019;71:793\u2013801. DOI: 10.1016\/j.jhep.2019.06.021","DOI":"10.1016\/j.jhep.2019.06.021"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.\n                      Metabolism\n                      . 2019;92:82\u201397. DOI: 10.1016\/j.metabol.2018.11.014","DOI":"10.1016\/j.metabol.2018.11.014"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: A systematic review and meta-analysis.\n                      Lancet Gastroenterol Hepatol\n                      . 2023;8:20\u201330. DOI: 10.1016\/S2468-1253(22)00317-X","DOI":"10.1016\/S2468-1253(22)00317-X"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.\n                      Hepatology\n                      . 2018;67:123\u201333. DOI: 10.1002\/hep.29466","DOI":"10.1002\/hep.29466"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention.\n                      Nat Rev Gastroenterol Hepatol\n                      . 2018;15:11\u201320. DOI: 10.1038\/nrgastro.2017.109","DOI":"10.1038\/nrgastro.2017.109"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Stepanova M, Ong J, et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the united states.\n                      Clin Gastroenterol Hepatol Mar\n                      . 2021;19:580\u20139. DOI: 10.1016\/j.cgh.2020.05.064","DOI":"10.1016\/j.cgh.2020.05.064"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis.\n                      Endocrinol Diabetes Metab\n                      . 2020;3:e00112. DOI: 10.1002\/edm2.112","DOI":"10.1002\/edm2.112"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease.\n                      Cell\n                      . 2021;184:2537\u201364. DOI: 10.1016\/j.cell.2021.04.015","DOI":"10.1016\/j.cell.2021.04.015"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies.\n                      Nat Med\n                      . 2018;24:908\u201322. DOI: 10.1038\/s41591-018-0104-9","DOI":"10.1038\/s41591-018-0104-9"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Angulo P, Machado MV, Diehl AM. Fibrosis in nonalcoholic fatty liver disease: Mechanisms and clinical implications.\n                      Semin Liver Dis\n                      . 2015;35:132\u201345. DOI: 10.1055\/s-0035-1550065","DOI":"10.1055\/s-0035-1550065"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Bansal MB, Chamroonkul N. Antifibrotics in liver disease: Are we getting closer to clinical use?\n                      Hepatol Int\n                      . 2019;13:25\u201339. DOI: 10.1007\/s12072-018-9897-3","DOI":"10.1007\/s12072-018-9897-3"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.\n                      Hepatology\n                      . 2017;65:1557\u201365. DOI: 10.1002\/hep.29085","DOI":"10.1002\/hep.29085"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.\n                      Gastroenterology\n                      . 2015;149:389\u201397. DOI: 10.1053\/j.gastro.2015.04.043","DOI":"10.1053\/j.gastro.2015.04.043"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic steatohepatitis: A review.\n                      JAMA\n                      . 2020;323:1175\u201383. DOI: 10.1001\/jama.2020.2298","DOI":"10.1001\/jama.2020.2298"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Younossi Z, Henry L. Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality.\n                      Gastroenterology\n                      . 2016;150:1778\u201385. DOI: 10.1053\/j.gastro.2016.03.005","DOI":"10.1053\/j.gastro.2016.03.005"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Mullur R, Liu Y-Y, Brent GA. Thyroid hormone regulation of metabolism.\n                      Physiol Rev\n                      . 2014;94:355\u201382. DOI: 10.1152\/physrev.00030.2013","DOI":"10.1152\/physrev.00030.2013"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Liangpunsakul S, Chalasani N. Is hypothyroidism a risk factor for non-alcoholic steatohepatitis?\n                      J Clin Gastroenterol\n                      . 2003;37:340\u20133. DOI: 10.1097\/00004836-200310000-00014","DOI":"10.1097\/00004836-200310000-00014"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Xu C, Xu L, Yu C, et al. Association between thyroid function and nonalcoholic fatty liver disease in euthyroid elderly Chinese.\n                      Clin Endocrinol (Oxf)\n                      . 2011;75:240\u20136. DOI: 10.1111\/j.1365-2265.2011.04016.x","DOI":"10.1111\/j.1365-2265.2011.04016.x"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Ludwig U, Holzner D, Denzer C, et al. Subclinical and clinical hypothyroidism and non-alcoholic fatty liver disease: A cross-sectional study of a random population sample aged 18 to 65 years.\n                      BMC Endocr Disord\n                      . 2015;15:41. DOI: 10.1186\/s12902-015-0030-5","DOI":"10.1186\/s12902-015-0030-5"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Bano A, Chaker L, Plompen EPC, et al. Thyroid function and the risk of nonalcoholic fatty liver disease: The Rotterdam study.\n                      J Clin Endocrinol Metab\n                      . 2016;101:3204\u201311. DOI: 10.1210\/jc.2016-1300","DOI":"10.1210\/jc.2016-1300"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Xu L, Ma H, Miao M, Li Y. Impact of subclinical hypothyroidism on the development of non-alcoholic fatty liver disease: A prospective case-control study.\n                      J Hepatol Nov\n                      . 2012;57:1153\u20134. DOI: 10.1016\/j.jhep.2012.05.025","DOI":"10.1016\/j.jhep.2012.05.025"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Mantovani A, Nascimbeni F, Lonardo A, et al. Association between primary hypothyroidism and nonalcoholic fatty liver disease: A systematic review and meta-analysis.\n                      Thyroid\n                      . 2018;28:1270\u201384. DOI: 10.1089\/thy.2018.0257","DOI":"10.1089\/thy.2018.0257"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Bruinstroop E, Dalan R, Cao Y, et al. Low-dose levothyroxine reduces intrahepatic lipid content in patients with type 2 diabetes mellitus and NAFLD.\n                      J Clin Endocrinol Metab\n                      . 2018;103:2698\u2013706. DOI: 10.1210\/jc.2018-00475","DOI":"10.1210\/jc.2018-00475"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Sinha RA, You S-H, Zhou J, et al. Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy.\n                      J Clin Invest\n                      . 2012;122:2428\u201338. DOI: 10.1172\/JCI60580","DOI":"10.1172\/JCI60580"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Sinha RA, Singh BK, Zhou J, et al. Thyroid hormone induction of mitochondrial activity is coupled to mitophagy via ROS-AMPK-ULK1 signaling.\n                      Autophagy\n                      . 2015;11:1341\u201357. DOI: 10.1080\/15548627.2015.1061849","DOI":"10.1080\/15548627.2015.1061849"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Bruinstroop E, Zhou J, Tripathi M, et al. Early induction of hepatic deiodinase type 1 inhibits hepatosteatosis during NAFLD progression.\n                      Mol Metab\n                      . 2021;53:101266. DOI: 10.1016\/j.molmet.2021.101266","DOI":"10.1016\/j.molmet.2021.101266"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Zhou J, Tripathi M, Ho JP, et al. Thyroid hormone decreases hepatic steatosis, inflammation, and fibrosis in a dietary mouse model of nonalcoholic steatohepatitis.\n                      Thyroid\n                      . 2022;32:725\u201338. DOI: 10.1089\/thy.2021.0621","DOI":"10.1089\/thy.2021.0621"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Bohinc BN, Michelotti G, Xie G, et al. Repair-related activation of Hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism.\n                      Endocrinology\n                      . 2014;155:4591\u2013601. DOI: 10.1210\/en.2014-1302","DOI":"10.1210\/en.2014-1302"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Saponaro F, Sestito S, Runfola M, et al. Selective thyroid hormone receptor-beta (TR\u03b2) agonists: New perspectives for the treatment of metabolic and neurodegenerative disorders.\n                      Front Med (Lausanne)\n                      . 2020;7:331. DOI: 10.3389\/fmed.2020.00331","DOI":"10.3389\/fmed.2020.00331"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Sinha RA, Singh BK, Yen PM. Direct effects of thyroid hormones on hepatic lipid metabolism.\n                      Nat Rev Endocrinol\n                      . 2018;14:259\u201369. DOI: 10.1038\/nrendo.2018.10","DOI":"10.1038\/nrendo.2018.10"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Sinha RA, Bruinstroop E, Singh BK, Yen PM. Nonalcoholic fatty liver disease and hypercholesterolemia: Roles of thyroid hormones, metabolites, and agonists.\n                      Thyroid\n                      . 2019;29:1173\u201391. DOI: 10.1089\/thy.2018.0664","DOI":"10.1089\/thy.2018.0664"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Chaves C, Bruinstroop E, Refetoff S, et al. Increased hepatic fat content in patients with resistance to thyroid hormone beta.\n                      Thyroid\n                      . 2021;31:1127\u201334. DOI: 10.1089\/thy.2020.0651","DOI":"10.1089\/thy.2020.0651"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Perra A, Simbula G, Simbula M, et al. Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit\/reverse nonalcoholic fatty liver in rats.\n                      FASEB J\n                      . 2008;22:2981\u20139. DOI: 10.1096\/fj.08-108464","DOI":"10.1096\/fj.08-108464"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Cable EE, Finn PD, Stebbins JW, et al. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist.\n                      Hepatology\n                      . 2009;49:407\u201317. DOI: 10.1002\/hep.22572","DOI":"10.1002\/hep.22572"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Sjouke B, Langslet G, Ceska R, et al. Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): A randomised, double-blind, placebo-controlled phase 3 study.\n                      Lancet Diabetes Endocrinol\n                      . 2014;2:455\u201363. DOI: 10.1016\/S2213-8587(14)70006-3","DOI":"10.1016\/S2213-8587(14)70006-3"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Vatner DF, Weismann D, Beddow SA, et al. Thyroid hormone receptor-\u03b2 agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways.\n                      Am J Physiol Endocrinol Metab\n                      . 2013;305:E89\u2013100. DOI: 10.1152\/ajpendo.00573.2012","DOI":"10.1152\/ajpendo.00573.2012"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Chaudhary P, Marracci GH, Calkins E, et al. Thyroid hormone and thyromimetics inhibit myelin and axonal degeneration and oligodendrocyte loss in EAE.\n                      J Neuroimmunol\n                      . 2021;352:577468. DOI: 10.1016\/j.jneuroim.2020.577468","DOI":"10.1016\/j.jneuroim.2020.577468"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Finan B, Clemmensen C, Zhu Z, et al. Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic impact for metabolic disease.\n                      Cell\n                      . 2016;167:843\u201357. DOI: 10.1016\/j.cell.2016.09.014","DOI":"10.1016\/j.cell.2016.09.014"},{"key":"ref44","unstructured":"ClinicalTrials.govA study to assess the efficacy and safety of VK2809 for 52 weeks in subjects with biopsy proven NASH (VOYAGE). ClinicalTrials.gov Identifier: NCT04173065. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04173065 (accessed date: 16 March 2023)"},{"key":"ref45","unstructured":"ClinicalTrials.gov.DUET study: A clinical study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of orally administered TERN-501 as monotherapy and in combination with TERN-101 in noncirrhotic adults with presumed non-alcoholic steatohepatitis. ClinicalTrials.gov Identifier: NCT05415722. : . Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05415722 (accessed date: 16 March 2023)"},{"key":"ref46","unstructured":"ClinicalTrials.govStudy to evaluate the safety, tolerability, and efficacy of ASC41 in adults with NASH. ClinicalTrials.gov Identifier: NCT05118360. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05118360 (Date last accessed: March 2023)"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.\n                      Lancet\n                      . 2019;394:2012\u201324. DOI: 10.1016\/S0140-6736(19)32517-6","DOI":"10.1016\/S0140-6736(19)32517-6"},{"key":"ref48","unstructured":"The Digital International Liver Congress. Abstract book. Available at: https:\/\/ilc-congress.eu\/wp-content\/uploads\/2020\/08\/digital-ilc-2020-abstract-book-20-august.pdf"},{"key":"ref49","unstructured":"European Association for the Study of the Liver. The International liver Congress. Abstract book. 2022. Available at: https:\/\/easl.eu\/wp-content\/uploads\/2022\/06\/ILC-2022-Abstract-Book-15.06-Web.pdf (Date last accessed: 18 April 2023)"},{"key":"ref50","unstructured":"Ascetis. Gannex announces positive phase I clinical results on its THR-\u03b2 agonist ASC41. 2021. Available at: www.ascletis.com\/news_detail\/175\/id\/454\/l\/en-us\/l\/en-us.html"},{"key":"ref51","unstructured":"Ascetis. Gannex announces positive clinical results in overweight and obese subjects for its THR-\u03b2 agonist ASC41. 2021. Available at: www.ascletis.com\/news_detail\/175\/id\/462\/l\/en-us.htm (Date last accessed: 11 April 2023)"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Kelly MJ, Pietranico-Cole S, Larigan JD, et al. Discovery of 2-[3,5-dichloro-4- (5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy) phenyl] -3,5-dioxo-2,3,4,5-tetrahydro [1,2,4] triazine-6-carbonitrile (MGL-3196), a highly selective thyroid hormone receptor \u03b2 agonist in clinical trials for the treatment of dyslipidemia.\n                      J Med Chem\n                      . 2014;57:3912\u201323. DOI: 10.1021\/jm4019299","DOI":"10.1021\/jm4019299"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"H\u00f6nes GS, Sivakumar RG, Hoppe C, et al. Cell-Specific transport and thyroid hormone receptor isoform selectivity account for hepatocyte-targeted thyromimetic action of MGL-3196.\n                      Int J Mol Sci\n                      . 2022;23:22. DOI: 10.3390\/ijms232213714","DOI":"10.3390\/ijms232213714"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Luong XG, Stevens SK, Jekle A, et al. Regulation of gene transcription by thyroid hormone receptor \u03b2 agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH).\n                      PLoS One\n                      . 2020;15:e0240338. DOI: 10.1371\/journal.pone.0240338","DOI":"10.1371\/journal.pone.0240338"},{"key":"ref55","unstructured":"Kelly GS. Peripheral metabolism of thyroid hormones: A review.\n                      Altern Med Rev\n                      . 2000;5:306\u201333."},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Bianco AC, Kim BW. Deiodinases: Implications of the local control of thyroid hormone action.\n                      J Clin Invest\n                      . 2006;116:2571\u20139. DOI: 10.1172\/JCI29812","DOI":"10.1172\/JCI29812"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Taub R, Chiang E, Chabot-Blanchet M, et al. Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-\u03b2 agonist.\n                      Atherosclerosis\n                      . 2013;230:373\u201380. DOI: 10.1016\/j.atherosclerosis.2013.07.056","DOI":"10.1016\/j.atherosclerosis.2013.07.056"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Harrison SA, Bashir M, Moussa SE, et al. Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH.\n                      Hepatol Commun\n                      . 2021;5:573\u201388. DOI: 10.1002\/hep4.1657","DOI":"10.1002\/hep4.1657"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Boyle M, Tiniakos D, Schattenberg JM, et al. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease.\n                      JHEP Rep\n                      . 2019;1:188\u201398. DOI: 10.1016\/j.jhepr.2019.06.004","DOI":"10.1016\/j.jhepr.2019.06.004"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Eddowes PJ, Sasso M, Allison M, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease.\n                      Gastroenterology\n                      . 2019;156:1717\u201330. DOI: 10.1053\/j.gastro.2019.01.042","DOI":"10.1053\/j.gastro.2019.01.042"},{"key":"ref61","unstructured":"ClinicalTrials.govA phase 3 study to evaluate the efficacy and safety of MGL-3196 (resmetirom) in patients with NASH and fibrosis (MAESTRO-NASH). ClinicalTrials.gov Identifier: NCT03900429. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03900429 (accessed date: 16 March 2023)"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Stepanova M, Taub RA, et al. Hepatic fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life.\n                      Clin Gastroenterol Hepatol\n                      . 2022;20:1354\u201361. DOI: 10.1016\/j.cgh.2021.07.039","DOI":"10.1016\/j.cgh.2021.07.039"},{"key":"ref63","unstructured":"US Food and Drug Administration. FDA approves ocaliva for rare, chronic liver disease. 2016. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-ocaliva-rare-chronic-liver-disease (Date last accessed: 11 April 2023)"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial.\n                      Lancet\n                      . 2015;385:956\u201365. DOI: 10.1016\/s0140-6736(14)61933-4","DOI":"10.1016\/S0140-6736(14)61933-4"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.\n                      Lancet\n                      . 2019;394:2184\u201396. DOI: 10.1016\/S0140-6736(19)33041-7","DOI":"10.1016\/S0140-6736(19)33041-7"},{"key":"ref66","unstructured":"ClinicalTrials.gov . Randomized global phase 3 study to evaluate the impact on NASH with fibrosis of obeticholic acid treatment (REGENERATE). ClinicalTrials.gov Identifier: NCT02548351. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02548351 (accessed date: 16 March 2023)"},{"key":"ref67","unstructured":"Madrigal. Madrigal announces positive topline results from the pivotal phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. 2022. Available at: https:\/\/ir.madrigalpharma.com\/news-releases\/news-release-details\/madrigal-announces-positive-topline-results-pivotal-phase-3 (Date last accessed: 11 April 2023)"},{"key":"ref68","unstructured":"ClinicalTrials.govA phase 3 study to evaluate the effect of resmetirom on clinical OUTCOMES in patients with well-compensated NASH cirrhosis (MAESTRO-NASH-OUTCOMES). ClinicalTrials.gov identifier: NCT05500222. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05500222 (accessed date: 16 March 2023)"}],"container-title":["European Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/touchendocrinology.com\/liver-disorders\/journal-articles\/resmetirom-an-orally-administered-small-molecule-liver-directed-?-selective-thr-agonist-for-the-treatment-of-non-alcoholic-fatty-liver-disease-and-non-alcoholic-steatohepatitis\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:59:28Z","timestamp":1764745168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.touchendocrinology.com\/liver-disorders\/journal-articles\/resmetirom-an-orally-administered-small-molecule-liver-directed-%CE%B2-selective-thr-agonist-for-the-treatment-of-non-alcoholic-fatty-liver-disease-and-non-alcoholic-steatohepatitis\/?rl=www.touchendocrinology.com\/liver-disorders\/journal-articles\/resmetirom-an-orally-administered-small-molecule-liver-directed-%CE%B2-selective-thr-agonist-for-the-treatment-of-non-alcoholic-fatty-liver-disease-and-non-alcoholic-steatohepatitis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"alternative-id":["EE.2023.19.1.60"],"URL":"https:\/\/doi.org\/10.17925\/ee.2023.19.1.60","relation":{},"ISSN":["1758-3772"],"issn-type":[{"value":"1758-3772","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}